English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduHackensack Meridian Neuroscience Institute at Jersey Shore University Medical Center successfully performed the first GammaTile® implant in the state. The device was implanted in a patient with recurrent meningioma, a brain tumor, to deliver radiation immediately at the time of surgery, targeting residual cancer cells to help prevent recurrence while minimizing harm to healthy tissue.
Tag: Brain Tumor
MD Anderson Research Highlights for February 7, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.
February 2024 Issue of Neurosurgical Focus: “Low-Grade Glioma in Adults: Contemporary Management”
Announcement of contents of the February 2024 issue of Neurosurgical Focus
Brain tumor treatment by targeting TUG1, a gene that controls replication stress
A new study has unravelled a crucial link between how cancer cells cope with replication stress and the role of Taurine Upregulated Gene 1 (TUG1). By targeting TUG1 with a drug, the researchers were able to control brain tumor growth in mice, suggesting a potential strategy to combat aggressive brain tumors such as glioblastomas.
Researchers awarded $2.5 million to develop brain cancer treatment
A multidisciplinary team of investigators from the UCLA Jonsson Comprehensive Cancer Center was awarded a $2.5 million Translational Team Science Award from the Department of Defense to develop a tailored treatment for glioblastoma, a deadly brain tumor with limited treatment options.
Study could help explain why certain brain tumors don’t respond well to immunotherapy
A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center sheds new light on why tumors that have spread to the brain from other parts of the body respond to immunotherapy while glioblastoma, an aggressive cancer that originates in the brain, does not.
Hackensack Meridian Neuroscience Institute Now Using QuicktomeTM Brain Mapping Technology To Visualize Key Areas of the Brain Related To Speech and Other Key Functions During Complex Brain Surgery
Brain mapping technology now available for complex brain surgeries at Hackensack Meridian Neuroscience Institute.
AI Tool Decodes Brain Cancer’s Genome During Surgery
New AI tool enables in-surgery genomic profiling of gliomas, the most aggressive and most common brain tumors.
New drug delays progression of glioma, a deadly brain cancer
In an international study co-led by UCLA, scientists have shown that a new targeted therapy drug can extend the amount of time people with a subtype of glioma are on treatment without their cancer worsening. The finding suggests a possible new treatment option for people with the slow-growing but deadly brain tumor.
Cancer cells rev up synthesis, compared with neighbors
Tumors are composed of rapidly multiplying cancer cells. Understanding which biochemical processes fuel their relentless growth can provide hints at therapeutic targets. Researchers from Washington University in St. Louis have developed a technology to study tumor growth in another dimension — literally. The scientists established a new method to watch what nutrients are used at which rates spatially throughout a tissue.
ASCO: Targeted therapy for early breast cancer, progress treating recurrent glioma, PSMA PET scan advances and more
Physicians and scientists from the UCLA Jonsson Comprehensive Cancer Center will discuss the latest research and clinical trial results on combination therapies for breast cancer, a potential new treatment for patients with recurrent glioma, and advances in PSMA PET guided radiotherapy for patients with prostate cancer, among other topics, at the American Society of Clinical Oncology’s annual meeting.
Study using novel approach for glioblastoma treatment shows promising results, extending survival
A new international study published in and presented as a late-breaking abstract at the American Association of Neurological Surgeons (AANS) annual conference, shows great promise for patients with glioblastoma. Drs. Farshad Nassiri and Gelareh Zadeh, neurosurgeons and scientists at the University Health Network (UHN) in Toronto, published the results of a Phase 1/2 clinical trial investigating the safety and effectiveness of a novel therapy which combines the injection of an oncolytic virus – a virus that targets and kills cancer cells – directly into the tumour, with intravenous immunotherapy.
Clinical trial improves neurocognitive outcomes for childhood craniopharyngioma
Investigators from St. Jude Children’s Research Hospital found that proton therapy had efficacy similar to conventional photon therapy with fewer negative neurocognitive outcomes. The clinical trial may set the new “gold standard” for pediatric craniopharyngioma treatment.
March Tip Sheet From Sylvester Comprehensive Cancer Center
A new study reported in JAMA Network Open unveils disparities in Mesothelioma survival, a grant to help construction workers nail quitting smoking, a new AI algorithm that offers insights into deadly cancer, a newly launched Neuroendocrine Tumors Program, a cancer researcher chosen to co-lead Tumor Biology Program and more are in this month’s tip sheet from Sylvester Comprehensive Cancer Center.
Artificial intelligence predicts genetics of cancerous brain tumors in under 90 seconds
Using artificial intelligence, researchers have discovered how to screen for genetic mutations in cancerous brain tumors in under 90 seconds — and possibly streamline the diagnosis and treatment of gliomas, a study suggests. The newly developed system, DeepGlioma, identified mutations used by the World Health Organization to define molecular subgroups of diffuse glioma with an average accuracy over 90%.
Advancing Care and Innovation for Pediatric Brain Tumors
The Brain Tumor Center at Children’s Hospital Los Angeles takes a team approach—and offers one of the largest clinical trial programs of its kind. The Brain Tumor Center at Children’s Hospital Los Angeles is one of the largest and most comprehensive pediatric brain tumor programs in the country, integrating experts from multiple specialty areas into a coordinated treatment team.
AANS/CNS Cerebrovascular Section and American Society of Stereotactic and Functional Neurosurgery Contribute to SNS Neurosurgeon-Scientist Training Program
The Cerebrovascular Section of the American Association of Neurological Surgeons and Congress of Neurological Surgeons and the American Society for Stereotactic and Functional Neurosurgery joined in supporting the Society of Neurological Surgeons newly launched Neurosurgeon-Scientist Training Program.
Unraveling the biology behind aggressive pediatric brain tumor reveals potential new treatment avenue
Researchers at the University of Michigan Rogel Cancer Center have identified a novel treatment approach to an aggressive type of pediatric brain cancer, using therapies already approved to treat cancer. The team developed a mouse model of pediatric glioma with a histone mutation called H3.3-G34, which allowed them to study the tumor’s biology in the presence of a functional immune system, revealing a promising outlook for long-term survival.
Henry Ford Health + MSU Health Sciences Funds Five Cancer Research Grants to Advance Cancer Medicine, Combat Health Disparities
Henry Ford Health + Michigan State University Health Sciences today announced its funding of five cancer research grants of up to $100,000 each. These five grants follow an initial wave of funding from the partnership, in which 18 pilot grants of up to $25,000 each were funded in May 2022.
MD Anderson to host virtual Cancer Neuroscience Symposium
MD Anderson will host the virtual Cancer Neuroscience Symposium Sept. 22-23, 2022, in collaboration with the journal Advanced Biology. The symposium is free to attend and gathers leading experts in the field to discuss a variety of topics on the relationship between cancer biology and neuroscience. Registration includes the opportunity to participate in an abstract competition and to view sessions following the event.
Sylvester Leads Study on New Treatment Option for Brain Tumor that Relapses or Fails to Respond to Standard of Care
Taken twice daily, oral olutasidenib helped to stabilize relapsed or refractory gliomas in heavily pretreated patients with less toxicity than standard of care treatment, according to a study led by Sylvester Comprehensive Cancer Center at the University of Miami School…
Noninvasive Brain Tumor Treatment Allows Physicians to treat tumors with Pinpoint Accuracy
Joseph P. Weiner, MD, radiation oncologist at Rutgers Cancer Institute and assistant professor of radiation oncology at Rutgers Robert Wood Johnson Medical School, who specializes in malignant and benign cancers of the brain and spine shares more about Gamma knife, a non-surgical treatment option that uses high doses of precisely focused radiation beams to destroy cancer cells and non-cancerous tumors.
Safety concerns raised for neuroblastoma candidate drug
St. Jude Children’s Research Hospital scientists have identified the primary target of the experimental cancer drug CX-5164, revealing a possible risk for late effects of treatment.
New study shows that different types of cancers are likely to spread to specific areas of the brain
Brain metastasis occurs when cancer in one part of the body spreads to the brain. The lifetime incidence of such metastatic brain tumors in cancer patients is between 20%-45%, research shows.
Study Sheds Light on Mechanism of Liposome Accumulation in Tumors
Dmitri Simberg, PhD, associate professor in the University of Colorado Skaggs School of Pharmacy, released a new study of the effectiveness of different types of fluorescent labels used to monitor the accumulation of liposomes in tumors. The study was published on July 1, 2021, in ACS Nano.
Brain tumors caused by normal neuron activity in mice predisposed to such tumors
Researchers at Washington University School of Medicine in St. Louis and Stanford University School of Medicine have found that normal exposure to light can drive the formation and growth of optic nerve tumors in mice — and maybe people — with a genetic predisposition. Such tumors can lead to vision loss.
Childhood Brain Tumors Linked to Mother’s Exposure to Pesticides
A UCLA-led study published in the peer-reviewed journal Environmental Research suggests that exposure during pregnancy to a wide variety of pesticides may lead to the development of central nervous system tumors during childhood.
Researchers identify potential therapeutic target against malignant brain tumors
Researchers at UAB have identified a potential new pathway to treating radiation-resistant glioblastoma, one of the most aggressive forms of brain cancer. The findings indicate that an adhesive cell surface protein known as N-cad may be key in overcoming glioblastoma’s resistance to radiation therapy.
New immunotherapy target discovered for malignant brain tumors
Scientists say they have discovered a potential new target for immunotherapy of malignant brain tumors, which so far have resisted the ground-breaking cancer treatment based on harnessing the body’s immune system. The discovery, reported in the journal CELL, emerged from laboratory experiments and has no immediate implications for treating patients.
Molecular Details Reveal New Clues about Common Brain Tumor
The largest and most detailed molecular analysis yet of an aggressive brain cancer, called glioblastoma, reveals fundamental details that drive its growth. The
Aggressive brain tumor mapped in genetic, molecular detail
A new study led by Washington University School of Medicine in St. Louis has revealed a detailed map of the genes, proteins, infiltrating cells and signaling pathways that play key roles in driving glioblastoma. The study, of 99 tumors from patients, is the largest and most detailed schematic of this deadly brain tumor.
February 2021 Issue of Neurosurgical Focus: “Gene and Viral Therapy for Glioblastoma Multiforme”
Announcement of articles in the February issue of neurosurgical Focus.
Ingo Mellinghoff Named Chair of MSK’s Department of Neurology
Neuro-oncologist and renowned physician-scientist Ingo Mellinghoff will lead MSK’s distinguished Department of Neurology after previously serving as Acting Co-Chair.
Rutgers Cancer Institute Researchers Utilize 4D Printing with Patient Derived Organoids to Accelerate Treatment Testing for Common Brain Tumor
Rutgers Cancer Institute investigator shares about a new project in which 4-dimensional (4D) printing of arrays that transform from cell-culture inserts into histological cassettes are utilized and hold patient tissue samples for rapid programmable drug testing to accelerate treatment testing for glioblastoma multiforme (GBM), a common brain tumor.
Brain Cancer: UVA IDs Gene Responsible for Deadly Glioblastoma
The discovery of the oncogene responsible for glioblastoma could be the brain tumor’s Achilles’ heel, one researcher says.
Roswell Park Studies Highlight Emerging Treatment Options for Neuroendocrine Tumors
Two new studies led by Renuka Iyer, MD, Section Chief for Gastrointestinal Oncology at Roswell Park Comprehensive Cancer Center, highlight possible new treatment options for patients with neuroendocrine tumors (NETs) — a rare and hard-to-treat cancer.
Focused ultrasound shows promise against deadliest brain tumor
An innovative use of focused ultrasound is showing promise against glioblastoma, the deadliest brain tumor, and could prove useful against other difficult-to-treat cancers.
Schizophrenia drug combined with radiation shows promise in treating deadly brain tumors
UCLA researchers found that adding a drug once commonly used to treat schizophrenia to traditional radiation therapy helped improve overall survival in mice with glioblastoma, one of the deadliest and most difficult-to-treat brain tumors.
Massive study reveals how “hypermutated” malignant brain tumors with many mutations escape chemotherapy and immunotherapy
An analysis of more than 10,000 gliomas and clinical outcomes reported in Nature by scientists in Boston and Paris found that glioma patients whose tumors were hypermutated actually had no significant benefit when treated with checkpoint blockers.
Targeting a transporter to treat SHH medulloblastoma
Scientists at St. Jude Children’s Research Hospital have identified a novel target for a type of pediatric brain tumor.
Bridging the gap between AI and the clinic Rapprocher l’IA de la pratique clinique
Researchers trained machine learning algorithms on data from more than 62,000 patients with a meningioma. Their goal was to find statistical associations between malignancy, survival, and a series of basic clinical variables including tumour size, tumour location, and surgical procedure.
Des chercheurs ont entraîné des algorithmes d’apprentissage automatique à partir des données de plus de 62 000 patients ayant un méningiome. L’objectif était de déceler des associations statistiques entre la malignité, le temps de survie et d’autres variables cliniques de base telles que la taille de la tumeur, son emplacement et la nature de l’intervention chirurgicale effectuée.
Study Uncovers Unexpected Connection Between Gliomas, Neurodegenerative Diseases
New basic science and clinical research identifies TAU, the same protein studied in the development of Alzheimer’s, as a biomarker for glioma development.
Zika Virus’ Key into Brain Cells ID’d, Leveraged to Block Infection and Kill Cancer Cells
Two different UC San Diego research teams identified the same molecule — αvβ5 integrin — as Zika virus’ key to brain cell entry. They found ways to take advantage of the integrin to both block Zika virus from infecting cells and turn it into something good: a way to shrink brain cancer stem cells.
3D brain tissue system aids study of deadly tumor progression
Made with extracellular matrix (ECM) from pig brains and seeded with tumors from patients, the system is revealing tumor/ECM interactions that aid tumor growth, providing potential targets for new therapies.
Blood Test Can Predict Prognosis in Deadly Brain Cancer
A blood test that measures the amount of cell-free DNA (cfDNA) in the bloodstream – called a liquid biopsy – correlates with how patients will progress after they are diagnosed with glioblastoma (GBM), the deadliest and most common primary brain tumor in adults
First Molecular Test in US to Better Detect Brain Tumors Now Available to Patients
NYU Langone Health and its Perlmutter Cancer Center have launched clinical whole genome DNA methylation profiling for patients with brain tumors.
This leading-edge molecular assay utilizes DNA epigenetic signatures and artificial intelligence with machine learning to correctly identify and subtype brain tumors. NYU Langone Health is the first Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory in the United States to receive state approval (New York State Department of Health) for whole genome DNA methylation for diagnosis and classification of brain tumors.
Sibling Bond Gets Brother with Large Brain Tumor the Best Care
When Gary Colon, 51, of Miami, Florida suddenly had trouble speaking, he called his sister, Becky, of Stratford, Connecticut for help. She urged him to go to an emergency department, where he had tests that revealed a meningioma. This large brain tumor was indenting and injuring the speech area of his brain.
Becky quickly made arrangements for Gary to come home and have brain surgery at Norwalk Hospital, where she’s worked for 17 years and knew he would get the best care.
Norwalk Hospital is equipped to handle these types of brain surgery cases because of the highly trained neurosurgeons, and seasoned physician assistants, nurses, medical assistants, operating room staff, and intensive care unit staff who work so well together.
CNS Gift to the CNS Foundation Doubles Innovative Clinical Research Initiative, Creating Annual NINDS/CNSF K12 Scholar Awards
The Congress of Neurological Surgeons Foundation (CNS Foundation) announced a second K12 award will be funded by a generous gift from the Congress of Neurological Surgeons (CNS). The award is made possible through a collaboration with the Foundation of the National Institutes of Health (FNIH) and the National Institutes of Health (NIH).